{
    "name": "technetium Tc 99m exametazime",
    "comment": "Rx",
    "other_names": [
        "Ceretec",
        "Drax Exametazime"
    ],
    "classes": [
        "Diagnostic Imaging Agents"
    ],
    "source": "https://reference.medscape.com/drug/ceretec-drax-exametazime-technetium-tc-99m-exametazime-1000191",
    "pregnancy": {
        "common": [
            "Limited available data with technetium Tc 99m exametazime use in pregnant women are insufficient to inform a drug associated risk for major birth defects and miscarriage",
            "Animal reproduction studies with technetium Tc 99m exametazime have not been conducted",
            "Inform patients who are pregnant or may become pregnant about the potential for adverse pregnancy outcomes based on the radiation dose from technetium Tc 99m exametazime and the gestational timing of exposure",
            "Limited data describes technetium Tc 99m exametazime crossing the placental barrier and visualization of radioactivity in the fetal liver; no adverse fetal effects or radiation-related risks have been identified for diagnostic procedures involving less than 50 mGy, which represents less than 10 mGy fetal doses"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Unknown if distributed in human breast milk",
            "To decrease radiation exposure to the breastfed infant, advise a lactating woman to pump and discard breast milk after administration of technetium Tc 99m exametazime-labeled leukocytes for 12-24 hours, where the duration corresponds to the typical range of administered activity, 259-925 MBq (7-25 mCi)",
            "Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Hypersensitivity reactions, including serious signs and symptoms of anaphylaxis, following administration of Tc 99m labeled leukocytes prepared using Tc 99m exametazime have been reported; monitor for hypersensitivity reactions and always have cardiopulmonary resuscitation equipment and personnel available",
                "Image interpretation may be affected by presence of other pathophysiological processes within and outside of the abdominal cavity (eg, tumor, infarction, trauma, and other inflammatory conditions)",
                "Technetium Tc 99m contributes to a patient’s overall long-term cumulative radiation exposure; long-term cumulative radiation exposure is associated with an increased risk of cancer; ensure safe handling and preparation reconstitution procedures to protect patients and health care workers from unintentional radiation exposure; encourage patients to drink fluids and void as frequently as possible after administration"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Hypersensitivity",
            "percent": null
        },
        {
            "name": "including anaphylaxis",
            "percent": null
        },
        {
            "name": "Cardiovascular",
            "percent": null
        },
        {
            "name": "Transient blood pressure increase",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue disorders",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "generalized erythema",
            "percent": null
        },
        {
            "name": "urticaria",
            "percent": null
        },
        {
            "name": "angioedema",
            "percent": null
        },
        {
            "name": "pruritus",
            "percent": null
        },
        {
            "name": "General disorders and administration site conditions",
            "percent": null
        },
        {
            "name": "Facial edema",
            "percent": null
        },
        {
            "name": "fever",
            "percent": null
        },
        {
            "name": "asthenic conditions",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "malaise",
            "percent": null
        },
        {
            "name": "fatigue",
            "percent": null
        },
        {
            "name": "Nervous system disorders",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "dizziness",
            "percent": null
        },
        {
            "name": "paresthesia",
            "percent": null
        },
        {
            "name": "Vascular disorders",
            "percent": null
        },
        {
            "name": "Flushing",
            "percent": null
        },
        {
            "name": "Gastrointestinal disorders",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "vomiting",
            "percent": null
        }
    ]
}